Dendritic cell vaccine transfected with hTERT-, survivin- and tumor cell derived mRNA (Oslo University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDendritic cell vaccine transfected with hTERT-, survivin- and tumor cell derived mRNA (Oslo University)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionTelomerase reverse transcriptase inhibitors

TargetsTelomerase reverse transcriptase

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesOslo University Hospital

China Registration ClassN/A

Develop Information

Active CompaniesOslo University Hospital

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A